This study further described the mutational profile in tumor tissue and blood for this type of cancer, and the investigation of genomic biomarkers for prediction of response to PD-1 inhibitors revealed a group of eight mutated genes that significantly correlated with non-responder status. Here, PDCD1 is linked to neoplasm.